MetaCap

Hemab Therapeutics (COAG) vs Vir Biotechnology (VIR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Hemab Therapeutics is the larger company by market cap ($1.84 billion vs $1.56 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COAG+15.56%VIR-16.10%
+66%+18%-31%
May 1, 20261 yearNov 20, 2026
COAG+15.56%VIR-16.10%
+66%+18%-31%
Apr 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COAG versus VIR key metrics
MetricCOAGVIR
Share price$39.29$8.39
Market cap$1.84B$1.56B
1-day change-1.43%-5.41%
YTD return—+39.14%
1-year return—+47.71%
5-year return—-76.69%
EPS (TTM)$-3.55$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$68.56M
Revenue growth (YoY)—-7.61%
Net income (latest FY)—$-437.99M
Gross margin—99.96%
Operating margin—-699.18%
Net margin—-638.87%
52-week high$55.42$14.38
52-week low$23.00$5.45
Distance from 52-week high-29.11%-41.66%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+60.35%+178.67%
Average volume495.96K2.45M
Shares outstanding46.73M186.27M
Employees59367
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Hemab Therapeutics

COAG stock →

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees

About Vir Biotechnology

VIR stock →

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 367 employees

COAG vs VIR FAQ

Which is bigger, Hemab Therapeutics or Vir Biotechnology?

Hemab Therapeutics (COAG) is larger, with a market capitalization of $1.84B compared with $1.56B for Vir Biotechnology (VIR).

Are Hemab Therapeutics and Vir Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons